171725-33-0

Basic information

• Product Name: 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline
• Synonyms: 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline
• CAS NO: 171725-33-0
• Molecular Weight: 438.524
• Mol File: 171725-33-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline(171725-33-0)
• EPA Substance Registry System: 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline(171725-33-0)

Safety Data

• Hazardous Substances Data: 171725-33-0(Hazardous Substances Data)

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 114552-32-8 N-tert-butoxycarbonyl-2-trimethylstannylaniline 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 

Downstream Products

• 171724-73-5 N-(tert-butoxycarbonylmethyl)-2-[4-(N-Cbz-piperidino)carbonyl]-N-{N'[m-(2-propenyloxycarbonyl)phenyl]uridomethylcarbamoyl}aniline 
• 171724-74-6 N-(tert-butoxycarbonylmethyl)-2-[4-(N-Cbz-piperidino)carbonyl]-N-[N'(m-carboxylphenyl)uridomethylcarbamoyl]aniline 
• 171725-35-2 2-[4-(N-Cbz-piperidino)carbonyl]-N-{N'[m-(2-propenyloxycarbonyl)phenyl]uridomethylcarbamoyl}aniline 
• 171725-34-1 2-(N'-CBz-piperidine-4-carbonyl)aniline 

Relevant articles and documents

Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509

A novel series of CCK-B/gastrin receptor antagonists - ureidomethylcarbamoylphenylketone derivatives - were designed, synthesized, and evaluated for activity. Structure-activity relationship studies revealed the importance of a carboxylic acid at substituent R2 and a tert-butoxycarbonyl group at R1 in structure A. Compound 7a (S-0509) showed remarkable affinity for the CCK-B/gastrin receptor and a subtype selectivity profile in vitro. Administration (id) of 7a led to excellent inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats with an ED50 value of 0.014 mg/kg. Furthermore, 7a proved to have poor blood-brain permeability by its small effect on enhancement of morphine analgesia. Thus, S-0509 has an increase in selectivity for the peripheral effects of gastrin antagonism from the central effects of CCK-B antagonism.